Why ISIS Pharmaceuticals, Inc. Catapulted 19% Higher in October
ISIS Pharmaceuticals was among October's top performing biotech stocks. Find out why ISIS catapulted higher by 19%, as well as whether or not this run can continue.
Arena Pharmaceuticals, Inc. Earnings: Looking for More
A prescription growth rate of 30% sounds good, but Belviq has such low sales, it's hard to get too excited yet. If phase 3 trials pan out, long-term growth will likely come from use as a smoking cessation drug and as a combination product for obesity.
Seattle Genetics, Inc. Posts Record Adcetris Sales
A solid quarter for the biotech allowed it to raise guidance for the year.